ArticleCell communication and signaling : CCS2024
Natural carboxyterminal truncation of human CXCL10 attenuates glycosaminoglycan binding, CXCR3A signaling and lymphocyte chemotaxis, while retaining angiostatic activity.
Article in Cell communication and signaling : CCS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- Active-targeted nano-hemostatic for hemostasis and brain microenvironment optimization in intracerebral hemorrhage therapy.Materials today. Bio · 2026Article
- Probing Glycosaminoglycan-Protein Interactions: Applications of Surface Plasmon Resonance.Biosensors · 2026Review
- A Spatiotemporal Model of CXCL10 as a Master Regulator of Immune Evasion and Metastasis in Osteosarcoma.International journal of molecular sciences · 2025Review
- CXCL10/CXCR3 axis facilitates the M2 polarization of macrophages in colorectal cancer via activating RAF.Discover oncology · 2025Article
- Characterization of Cytokine Treatment on Human Pancreatic Islets by Top-Down Proteomics.Proteomics · 2025Article
- Proteoglycans and glycosaminoglycans: critical regulators in angiogenesis, vasculogenesis, and vascularized tissue engineering.Angiogenesis · 2025Review
- Macrophage-Centric Immunometabolic Crosstalk in Alopecia Areata Pathogenesis: Mechanisms and Therapeutic Implications.Clinical reviews in allergy & immunology · 2025Review
- Characterization of cytokine treatment on human pancreatic islets by top-down proteomics.bioRxiv : the preprint server for biology · 2025Article
- Identification of biomarkers and construction of discriminating model for tuberculosis patients with diabetes mellitus based on proteomics: a cross-sectional study.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundInterferon-γ-inducible protein of 10 kDa (IP-10/CXCL10) is a dual-function CXC chemokine that coordinates chemotaxis of activated T cells and natural killer (NK) cells via interaction with its G protein-coupled receptor (GPCR), CXC chemokine receptor 3 (CXCR3). As a consequence of natural posttranslational modifications, human CXCL10 exhibits a high degree of structural and functional heterogeneity. However, the biological effect of natural posttranslational processing of CXCL10 at the carboxy (C)-terminus has remained partially elusive. We studied CXCL10
methodsRelative levels of CXCL10
resultsNatural CXCL10
conclusionOur study shows that the C-terminal residues Lys
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.